Ying Zhu
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ying
Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Author Correction: Parkinson’s disease as a somato-cognitive action network disorder
Correction to: Nature https://doi.org/10.1038/s41586-025-10059-1 Published online 4 February 2026 In the version of this article initially published, the Competing interests statement was incomplete. The Competing interests statement should have read: “H.L. is a co-founder and chief scientist of Neural Galaxy and Galaxy Brain Scientific. W.Z. and P.Z. were employed by Neural Galaxy during the period in which this research was conducted, in addition to their affiliation with Changping Laboratory.
Polyacrylamide Graft Modification of Alkali Lignin for Formaldehyde-Free Wood Adhesives With Enhanced Bonding Strength, Fracture Resistance, and Water Resistance
1 Introduction Wood-based composites serve as crucial carriers for the efficient utilization of wood resources and the advancement of residential materials. The adhesives employed significantly influence their manufacturing efficiency, service performance, and environmental safety. Presently, formaldehyde-based resins, including urea-formaldehyde, phenol-formaldehyde, and melamine-formaldehyde, dominate the adhesive systems in the wood industry [1].
Efficacy and safety of GC001: an oncolytic vaccinia virus expressing STRIP1 shRNA
Abstract GC001, a thymidine kinase deleted oncolytic vaccinia virus expressing striatin-interacting protein 1 (STRIP1) shRNA, has been approved by National Medical Products Administration (NMPA) of China to enter phase I clinical trial in 2023. Anti-tumour efficacy of GC001 across multiple cancer types was evaluated in mouse xenograft models. Anti-tumour immune responses were investigated in immunocompetent or humanised cancer mouse model.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ying
Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack